2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine | 1616086-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine
• CAS: 1616086-20-4
• 化学式: C₁₃H₁₄ClN₅
• 分子量: 275.741
• InChiKey: UDHKNKCIAMFJLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,4-二甲基哌啶 、 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 在 三乙胺 作用下， 以 异丙醇 为溶剂， 反应 12.0h， 生成 N-(5-cyclopropyl-1H-pyrazol-3-yl)-6,7-dihydro-2-(4,4-dimethylpiperidin-1-yl)-5h-cyclopenta[d]pyrimidin-4-amine
  参考文献：
  名称：

  Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor

  摘要：

  A series of novel 2-amino-4-pyrazolecyclopentylpyrimidines have been prepared and evaluated as IGF-1R tyrosin kinase inhibitors. The in vitro activity was found to depend strongly on the substitution pattern in the 2- amino ring, 4-pyrazolo moieties and size of fused saturated ring with the central pyrimidine core. A stepwise optimization by combination of active fragments led to discovery of compound 6f and 6k, two structures with IGF-1R IC50 of 20 nM and 10 nM, respectively. 6f was further profiled for its anti cancer activity across various cell lines and pharmacokinetic studies in Sprague Dawley rats. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.12.053
• 作为产物：
  描述：

  2-氧代环戊羧酸乙酯 在 盐酸 、 三乙胺 、 三氯氧磷 作用下， 以 乙醇 、 水 为溶剂， 反应 60.0h， 生成 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine
  参考文献：
  名称：

  Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor

  摘要：

  A series of novel 2-amino-4-pyrazolecyclopentylpyrimidines have been prepared and evaluated as IGF-1R tyrosin kinase inhibitors. The in vitro activity was found to depend strongly on the substitution pattern in the 2- amino ring, 4-pyrazolo moieties and size of fused saturated ring with the central pyrimidine core. A stepwise optimization by combination of active fragments led to discovery of compound 6f and 6k, two structures with IGF-1R IC50 of 20 nM and 10 nM, respectively. 6f was further profiled for its anti cancer activity across various cell lines and pharmacokinetic studies in Sprague Dawley rats. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.12.053

文献信息

• FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20140179668A1

  公开（公告）日：2014-06-26

  Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.

  提供了融合嘧啶化合物作为激酶抑制剂，如多激酶抑制剂。提供了融合嘧啶化合物作为IGF-IR抑制剂。这些化合物可用于治疗癌症的方法。还提供了含有融合嘧啶化合物和药用载体的药物组合物，以及含有融合嘧啶化合物或其盐和使用说明的试剂盒，例如用于治疗癌症的方法。
• [EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS MULTI-KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES UTILISÉS COMME INHIBITEURS DE PLUSIEURS KINASES
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2015028848A1

  公开（公告）日：2015-03-05

  The present invention provides bicyclic heterocyclic compounds (the compounds of formula I, or an isotopic form, a stereoisomer or a tautomer or a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug or N-oxide thereof and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders associated with abnormal protein kinase activity.

  本发明提供了双环杂环化合物（式I的化合物，或同位素形式、立体异构体、互变异构体或药学上可接受的盐、溶剂合物、多晶型、前药或N-氧化物及其制备方法。本发明还涉及含有所述化合物的药物组合物以及它们在治疗与异常蛋白激酶活性相关的疾病或紊乱中的用途。
• CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR
  申请人：Auspex Pharmaceuticals, Inc.

  公开号：US20140286943A1

  公开（公告）日：2014-09-25

  The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

  本发明涉及P2Y12受体活性的新的环丙基调节剂，其制药组合物以及使用方法。
• US9422267B2
  申请人：——

  公开号：US9422267B2

  公开（公告）日：2016-08-23
• US9499519B2
  申请人：——

  公开号：US9499519B2

  公开（公告）日：2016-11-22